Neurofeedback is effective but not widely known because it isn’t backed by pharmaceutical marketing, isn’t part of standard medical training, and is designed to reduce long-term dependence on treatment rather than create it.

That explanation may sound surprising, but it reflects how most people are introduced to healthcare options.

Most treatments people recognize are heavily marketed.
Medications and medical devices are often supported by large companies that spend hundreds of millions of dollars educating physicians and advertising to the public. Neurofeedback is based on non-proprietary technology — no single company owns it — which means there is no large marketing engine promoting it.

Most physicians are not trained in neurofeedback.
Medical education is already highly specialized and time-constrained. Neurofeedback sits at the intersection of neuroscience, psychology, learning theory, and technology, and it is not part of standard medical curricula. If a provider hasn’t pursued additional education in this area, they may simply be unfamiliar with when or how to recommend it.

Much of the research has historically lived outside mainstream medical journals.
Neurofeedback has a substantial research base, but many studies have been published in specialized neuroscience and biofeedback journals rather than the publications most physicians routinely read. That is changing, and awareness continues to grow as more research reaches broader clinical audiences.

Neurofeedback is not designed for indefinite use.
Unlike treatments that require ongoing consumption or repeated intervention, neurofeedback focuses on helping the brain learn more stable patterns of self-regulation. Once that learning has occurred, continued training is often unnecessary. This makes it less visible as a “product,” but more aligned with long-term change.

Regulation prioritizes safety over mass exposure.
Neurofeedback systems must meet regulatory requirements and are typically used by, or under the supervision of, licensed healthcare providers, including oversight from the U.S. Food and Drug Administration. This protects clients, but it also limits consumer-level promotion.

The bottom line:
Neurofeedback hasn’t been ignored because it doesn’t work — it has been under-promoted because it doesn’t fit the traditional medical or commercial model. As interest in non-drug, brain-based approaches continues to grow, neurofeedback is becoming far more visible than it was even a decade ago.